Tools
Tools
JAMESON, Adam, FAISAL, Muhammad, FYLAN, Beth, BRISTOW, Greg C., SOHAL, Jaspreet, DALTON, Caroline, SAGOO, Gurdeep S., CARDNO, Alastair G. and MCLEAN, Samantha L. (2024). Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study. Journal of Psychopharmacology, 38 (4), 382-394.
|
PDF
10.1177_02698811241238283.pdf - Published Version Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Background:: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual’s genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual’s genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants (‘CYP2D6-PGx antipsychotics’). Aims:: This study aims to investigate differences between demographic groups prescribed ‘CYP2D6-PGx antipsychotics’ and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance. Methods:: A cross-sectional study took place extracting data from 243 patients’ medical records to explore psychosis drug prescribing, including drug transitions. Demographic data such as age, sex, ethnicity, and clinical sub-team were collected and summarised. Descriptive statistics explored the proportion of ‘CYP2D6-PGx antipsychotic’ prescribing and the nature of transitions. We used logistic regression analysis to investigate associations between demographic variables and prescription of ‘CYP2D6-PGx antipsychotic’ versus ‘non-CYP2D6-PGx antipsychotic’. Results:: Two-thirds (164) of patients had been prescribed a ‘CYP2D6-PGx antipsychotic’ (aripiprazole, risperidone, haloperidol or zuclopenthixol). Over a fifth (23%) of patients would have met the suggested criteria for PGx testing, following two psychosis drug trials. There were no statistically significant differences between age, sex, or ethnicity in the likelihood of being prescribed a ‘CYP2D6-PGx antipsychotic’. Conclusions:: This study demonstrated high rates of prescribing ‘CYP2D6-PGx-antipsychotics’ in an EIP cohort, providing a rationale for further exploration of how PGx testing can be implemented in EIP services to personalise the prescribing of drugs for psychosis.
| Item Type: | Article |
|---|---|
| Additional Information: | ** Embargo end date: 17-03-2024 ** From SAGE Publishing via Jisc Publications Router ** Licence for this article starting on 17-03-2024: https://creativecommons.org/licenses/by/4.0/ ** Peer reviewed: TRUE **Journal IDs: pissn 0269-8811; eissn 1461-7285 **Article IDs: publisher-id: 10.1177_02698811241238283 **History: published_online 17-03-2024 |
| Uncontrolled Keywords: | Receptor Antagonist (D2, 5-HT2, NE, alpha-2), Receptor Antagonist (D2), Pharmacogenetics, Pharmacogenomics, Psychosis, Receptor Partial Agonist (D2, 5-HT1A), Schizophrenia, Receptor Antagonist (D2, 5-HT2), Personalised Medicine, Antipsychotics |
| Identification Number: | https://doi.org/10.1177/02698811241238283 |
| Page Range: | 382-394 |
| SWORD Depositor: | Colin Knott |
| Depositing User: | Colin Knott |
| Date Deposited: | 17 Apr 2024 15:58 |
| Last Modified: | 17 Apr 2024 16:00 |
| URI: | https://shura.shu.ac.uk/id/eprint/33580 |
Actions (login required)
 |
View Item |
Downloads
Downloads per month over past year